4/25
07:12 am
dnth
Nucleome Therapeutics appoints Dr John Davis as Non-Executive Director of the Board and establishes Scientific Advisory Board of world-leading experts [Yahoo! Finance]
Low
Report
Nucleome Therapeutics appoints Dr John Davis as Non-Executive Director of the Board and establishes Scientific Advisory Board of world-leading experts [Yahoo! Finance]
4/18
01:18 pm
dnth
Dianthus Therapeutics, Inc. (NASDAQ: DNTH) had its price target raised by analysts at Raymond James from $34.00 to $51.00. They now have an "outperform" rating on the stock.
Low
Report
Dianthus Therapeutics, Inc. (NASDAQ: DNTH) had its price target raised by analysts at Raymond James from $34.00 to $51.00. They now have an "outperform" rating on the stock.
4/11
07:30 am
dnth
Dianthus Therapeutics Announces Oral Presentation for DNTH103 at the 2024 American Academy of Neurology (AAN) Annual Meeting
Medium
Report
Dianthus Therapeutics Announces Oral Presentation for DNTH103 at the 2024 American Academy of Neurology (AAN) Annual Meeting
4/5
04:30 pm
dnth
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3/25
11:53 am
dnth
Dianthus Therapeutics, Inc. (NASDAQ: DNTH) had its price target raised by analysts at Jefferies Financial Group Inc. from $22.00 to $39.00. They now have a "buy" rating on the stock.
Low
Report
Dianthus Therapeutics, Inc. (NASDAQ: DNTH) had its price target raised by analysts at Jefferies Financial Group Inc. from $22.00 to $39.00. They now have a "buy" rating on the stock.
3/22
10:24 am
dnth
Dianthus Therapeutics, Inc. (NASDAQ: DNTH) had its price target raised by analysts at Wedbush from $24.00 to $33.00. They now have an "outperform" rating on the stock.
Medium
Report
Dianthus Therapeutics, Inc. (NASDAQ: DNTH) had its price target raised by analysts at Wedbush from $24.00 to $33.00. They now have an "outperform" rating on the stock.
3/21
04:14 pm
dnth
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY2023 Financial Results [Yahoo! Finance]
High
Report
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY2023 Financial Results [Yahoo! Finance]
3/21
04:01 pm
dnth
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY2023 Financial Results
High
Report
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY2023 Financial Results
3/7
04:30 pm
dnth
Dianthus Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Dianthus Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2/26
07:07 am
dnth
Dianthus Therapeutics Announces Initiation of Phase 2 MaGic Trial of DNTH103 In Generalized Myasthenia Gravis (gMG) [Yahoo! Finance]
Low
Report
Dianthus Therapeutics Announces Initiation of Phase 2 MaGic Trial of DNTH103 In Generalized Myasthenia Gravis (gMG) [Yahoo! Finance]
2/26
07:00 am
dnth
Dianthus Therapeutics Announces Initiation of Phase 2 MaGic Trial of DNTH103 In Generalized Myasthenia Gravis (gMG)
Low
Report
Dianthus Therapeutics Announces Initiation of Phase 2 MaGic Trial of DNTH103 In Generalized Myasthenia Gravis (gMG)
2/15
03:42 pm
dnth
Stifel starts Dianthus at buy, cites market potential of lead drug [Seeking Alpha]
Low
Report
Stifel starts Dianthus at buy, cites market potential of lead drug [Seeking Alpha]
2/15
07:17 am
dnth
Dianthus Therapeutics, Inc. (NASDAQ: DNTH) is now covered by analysts at Stifel Nicolaus. They set a "buy" rating and a $44.00 price target on the stock.
Low
Report
Dianthus Therapeutics, Inc. (NASDAQ: DNTH) is now covered by analysts at Stifel Nicolaus. They set a "buy" rating and a $44.00 price target on the stock.